Objective
US based biotech company having a complex portfolio of discovery, pre-clinical and development stage small molecules and biologics (Phase I-IV), with numerous projects at various stages of development. They wanted to design a single platform to manage all their development projects efficiently and explore the licensing opportunities. The complete assignment involve following activities-
- Conducting an independent evaluation of their research and development (R&D) portfolio
- Identifying preclinical commercial opportunities in the pipeline and developing a category matrix
- An assessment of future commercial potential and competitive threats
- Identifying key clinical development and commercial risks in developing the portfolio
- Evaluating key molecules and companies targeting metastatic breast cancer patients globally
Approach
eQuantX employed a comprehensive approach involving several key steps. Initially, the team focuses on mapping the asset-specific scientific and commercial attributes, creating a comparison matrix to effectively prioritize key companies and assets in the metastatic breast cancer space. This involves a thorough analysis of various indicators, including current standard of care and potential unmet needs. The next step involved a thorough examination of the probability of both combination and mono-therapy strategies for all prioritized assets. To refine the selection further, the team shortlists key companies and assets based on client-defined indicators such as company financial positions, portfolio freshness index, revenue from mature products, revenue from pipeline assets, and R&D and commercialization capabilities. By adopting this multifaceted approach, the project aimed to develop robust commercial portfolio strategies tailored to the complex landscape of metastatic breast cancer. Furthermore, the products profiles, business strengths, market attractiveness factors were ranked by company employees by comparing attributes across intended product profiles.
Outcome
The output summary included a comprehensive perception mapping and matrix-style presentation delivered to the client team. Following a voice of business survey with input from relevant company stakeholders, the results underwent careful weighting across various factors. This weighting took into account team inputs, the significance of strategic factors relative to other considerations, and the expertise of employees in their respective product categories. The received inputs are being utilized to inform the portfolio optimization model, aligning with client feedback. The output help client in identifying potential acquisition targets that make the most strategic sense for the portfolio. Additionally, it has facilitated the identification of potential licensing partners, further enhancing the overall commercial portfolio strategy in Metastatic Breast Cancer space.
